Tailoring Natural Effector Functions: Antibody Engineering Beyond Humanization
A large number of new biological drugs in clinical development from the biotechnology industry are based on recombinant antibodies. The Food and Drug Administration (FDA) has recently approved several of these drugs including reagents against cancer (1 ,2 ), transplant rejection (3 ), rheumatoid arthritis, and Crohn’s diseases (4 ,5 ) as well as antiviral prophylaxis (6 ). At present 30% of all biological proteins in application for FDA approvals are recombinant antibodies. Some are based on fusions of murine variable regions with human constant region, called chimeric antibodies. Others are more sophisticated being “humanized” from their mouse monoclonal parent molecule, whereas more recently full human antibodies from phage antibody libraries have been generated (7 ).
- Circulating Tumor Cells as Prognostic Biomarkers in Cutaneous Melanoma Patients
- Methods for the Study of Protein-Protein Interactions in Cancer Cell Biology
- Production of Tumor-Specific Antibodies in Tobacco
- Animal Models of Prostate Cancer
- Dendritic Cell/Myeloma Hybrid Vaccine
- Use of Nucleotide Excision Repair-Deficient Mice as a Model For Chemically Induced Lung Cancer
- Assembling a Tumor Progression Model
- Single Cell and Spheroid Collagen Type I Invasion Assay
- Production of Antibody Fragments in a Bioreactor
- 免疫磁珠分選的問題